Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler
Hangzhou‑based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai‑listed Huadong Medicine...
Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform
Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all...
Mirxes Secures China’s First Blood‑Test Approval for Gastric‑Cancer Screening
Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in‑vitro diagnostic (IVD) test, GASTROClear,...
Jenscare Secures LuX‑Valve Approval for Transjugular Tricuspid Replacement in Greater Bay Area
Jenscare Scientific Co., Ltd (HKG: 9877) announced that its LuX‑Valve Plus transjugular tricuspid valve replacement...
Roche Secures FDA Approval for Tecentriq‑Lurbinectedin Combo in ES‑SCLC
Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA)...
Eli Lilly to Invest $1B in India, Launch New Hyderabad Manufacturing Hub
Eli Lilly & Co. (NYSE: LLY) has announced a commitment to invest more than USD 1 billion...
Walvax Biotech Wins Jordan FDA Approval for 13‑Valent Pneumococcal Vaccine
China‑based Walvax Biotechnology Co., Ltd. (SHE: 300142) has secured market approval from the Jordan Food...
Northeast Pharma Secures NMPA Approval for DCTY0801 Injection Targeting EGFRvIII‑Positive Brain Gliomas
China‑based Northeast Pharmaceutical Group Co., Ltd. (SHE: 000597) has announced that its chimeric antigen receptor...
InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline
InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas...
Hengrui, SHR‑4298, RAS: China Approves Two Novel Anti‑Tumor Drugs for Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration...
Shanghai Fosun Secures NMPA Approval for HLX43 + HLX07 Combination in Advanced Solid Tumors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the National Medical Products Administration...
RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema
China‑based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) and Japan’s Santen Pharmaceutical Co., Ltd. confirmed...
AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure
AstraZeneca plc (AZ; NASDAQ: AZN) has unveiled a plan to standardise its share‑listing structure across...
C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar
C‑MER Medical Holdings Limited (HKG: 3309) announced that its joint‑venture arm, Health Hope Pharma Limited...
NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs
The National Medical Products Administration (NMPA) has issued a new regulatory framework, titled “Announcement on...
MicroPort Announces $680 Million Merger with CRM Cayman, Expanding Cardio‑Medical Footprint
MicroPort Scientific Corporation (HKG: 0853) disclosed that CRM Cayman, MicroPort CardioFlow Medtech Corporation, and MicroPort CardioFlow...
Shanghai Junshi Biosciences Announces Nearly RMB 380 Million Capital Increase for Grit Biotechnology
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) disclosed that its subsidiary, Shanghai JunTop...
AccurEdit Therapeutics Raises $75 M Series A, Secures Strategic Partners for Gene‑Editing Platform
China‑based AccurEdit Therapeutics (Suzhou) Co., Ltd. announced that it has closed a US$75 million Series A financing...
Changchun GeneScience Secures China Approval for Long‑Acting FSH‑CTP Injection
China‑based Changchun GeneScience Pharmaceutical Co. Ltd. announced that its long‑acting recombinant human follicle‑stimulating hormone—CTP fusion...
Ipsen Launches BYLVAY in China for Rare Liver Disease
France‑based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the official commercial launch of its rare‑disease...